Google open-sourced Harness2, a recursive agent harnessing framework that lifted GLM-5 11.5 points on WorkBuddy-Bench with ...
Recursion Pharmaceuticals Inc. stocks have been trading up by 14.44 percent following pivotal AI-driven drug discovery ...
As AI companies warn of the dangers of self-improving AI, a new report offers a rare look at how they’re working to make it a ...
Recursion Pharmaceuticals Inc. RXRX shares are trending on Friday. Shares of the Utah-based clinical-stage biotechnology ...
Since I called it three times in the recursion, the return process also happens three times. Even though I understood it in ...
Recursion (RXRX) stock dips after $200M equity offering despite Sanofi (SNY) choosing its first AI drug candidate under a ...
Recursion Pharma launches a $200M equity offering and reports a Sanofi milestone but is rated a Hold on limited near-term ...
There has been another major milestone in the field of AI-driven drug discovery (AI drug discovery).I would like to organize ...
Leading Healthcare Investors, including Janus Henderson Investors, Invus, Longaeva Partners, ARK Invest, Driehaus Capital ...
If the current levels hold, RXRX stock would record its biggest single-day gains in almost a year.
Recursion Pharmaceuticals Inc. stocks have been trading down by -8.72 percent after bearish analyst coverage questioned its ...
Prices displayed are informational. Learn more Recursion Pharmaceuticals (RXRX) said Thursday it priced an offering of 61.5 million shares at $3.25 each to raise gross proceeds of about $200 million.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results